The study investigated the safety and efficacy of Pregabalin (CI-1008) in the treatment of fibromyalgia.
The results of the trial showed reduction in the endpoint mean pain score with pregabalin in comparison to placebo.
The trial involved around 501 patients (251 pregabalin and 250 placebo) in 45 investigative sites in Japan.
Pfizer Japan Development head and vice president Akihisa Harada said they look forward to more fully understanding the potential benefits that Lyrica may bring to fibromyalgia patients in Japan.